Effectiveness comparisons of drug therapies for postoperative aneurysmal subarachnoid hemorrhage patients: network meta‑analysis and systematic review
Open Access
- 27 July 2021
- journal article
- review article
- Published by Springer Nature in BMC Neurology
- Vol. 21 (1) , 1-13
Abstract
Objective: To compare the effectiveness of various drug interventions in improving the clinical outcome of postoperative patients after aneurysmal subarachnoid hemorrhage (aSAH) and assist in determining the drugs of definite curative effect in improving clinical prognosis.Methods: Eligible Randomized Controlled Trials (RCTs) were searched in databases of PubMed, EMBASE, and Cochrane Library (inception to Sep 2020). Glasgow Outcome Scale (GOS) score, Extended Glasgow Outcome Scale (GOSE) score or modified Rankin Scale (mRS) score was used as the main outcome measurements to evaluate the efficacy of various drugs in improving the clinical outcomes of postoperative patients with aSAH. The network meta-analysis (NMA) was conducted based on a random-effects model, dichotomous variables were determined by using odds ratio (OR) with 95% confidence interval (CI), and a surface under the cumulative ranking curve (SUCRA) was generated to estimate the ranking probability of comparative effectiveness among different drug therapies.Results: From the 493 of initial citation screening, forty-four RCTs (n = 10,626 participants) were eventually included in our analysis. Our NMA results showed that cilostazol (OR = 3.35,95%CI = 1.50,7.51) was the best intervention to improve the clinical outcome of patients (SUCRA = 87.29%, 95%CrI 0.07–0.46). Compared with the placebo group, only two drug interventions [nimodipine (OR = 1.61, 95%CI 1.01,2.57) and cilostazol (OR = 3.35, 95%CI 1.50, 7.51)] achieved significant statistical significance in improving the clinical outcome of patients.Conclusions: Both nimodipine and cilostazol have exact curative effect to improve the outcome of postoperative patients with aSAH, and cilostazol may be the best drug to improve the outcome of patients after aSAH operation. Our study provides implications for future studies that, the combination of two or more drugs with relative safety and potential benefits (e.g., nimodipine and cilostazol) may improve the clinical outcome of patients more effectively.Keywords
All Related Versions
This publication has 88 references indexed in Scilit:
- Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trialThe Lancet, 2012
- Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular CoilingStroke, 2012
- Guidelines for the Management of Aneurysmal Subarachnoid HemorrhageStroke, 2012
- Effect of magnesium sulfate therapy on patients with aneurysmal subarachnoid hemorrhage using serum S100B protein as a prognostic markerNeurosurgical Review, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: A randomized, placebo-controlled, clinical study*Critical Care Medicine, 2010
- Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic reviewThe Lancet Neurology, 2009
- Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trialActa Neurochirurgica, 2007
- Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhageJournal of Neurosurgery, 2002
- Therapeutic Trial of Intravenous Nimodipine in Patients with Established Cerebral Vasospasm after Rupture of Intracranial AneurysmsNeurosurgery, 1988